Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins

Journal of Pharmaceutical Sciences

Volumn 89, Issue 8, 2000, Pages 1008-1021

  Schuhmacher, Joachim ^a   Bühner, Klaus ^a   Witt Laido, Astrid ^a  

^a BAYER AG   (Germany)

Author keywords

Adsorption problems; Erythrocyte plasma distribution; Highly protein bound drugs; Protein binding; Species differences; Ultrafiltration

Indexed keywords

PLASMA PROTEIN;

AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; DRUG DETERMINATION; ERYTHROCYTE MEMBRANE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; RECEPTOR BINDING; SPECIES DIFFERENCE; ULTRAFILTRATION;

EID: 0033822309     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200008)89:8<1008::AID-JPS5>3.0.CO;2-B     Document Type: Article

References (42)

1. Free drug measurements: Methodology and clinical significance
2. Free drug concentration monitoring in clinical practice: Rationale and current status
3. Rationale for monitoring free drug levels
4. The influence of protein binding on vasoactivity
5. Methods of drug protein binding determinations
6. Methods of determining plasma and tissue binding of drugs
7. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin
8. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
9. Comparison of five methods for the study of drug-protein binding in affinity capillary electrophoresis
10. Theoretical study of high-performance frontal analysis: A chromatographic method for determination of drug-protein interaction
11. HPLC study of the binding of sulfinpyrazone to serum albumin
12. High-performance frontal analysis for the determination of the free drug concentration in protein binding equilibrium using porous polymer stationary phase
13. Direct determination of protein binding of phenytoin in serum by high-performance liquid chromatography
14. Determination of the unbound concentration of hydrophobic drugs in albumin solutions by high-performance frontal analysis using a diol-silica column
15. Micro high-performance frontal analysis for simultaneous determination of unbound and total carbamazepine concentrations in protein binding equilibrium
16. Separation procedures used to reveal and follow drug-protein binding
17. Hummel-Dreyer method in high-performance liquid chromatography for the determination of drug-protein binding parameters
18. Chromatographic measurement of drug-protein interaction: Determination of HIV protease inhibitor-serum albumin association
19. Study of protein-drug binding by capillary zone electrophoresis: Prospects and problems
20. Use of a human serum albumin-based stationary phase for high-performance liquid chromatography as a tool for the rapid determination of drug-plasma protein binding
21. Determination of drug protein-binding by high-performance liquid chromatography using a chemically Bonded Bovine albumin stationary phase
22. Determination of the magnitude and enantioselectivity of ligand binding to rat and rabbit serum albumins using immobilized-protein high performance liquid chromatography stationary phases
23. High-performance liquid chromatographic assay of methadone, phencyclidine, and metabolites by postcolumn ion-pair extraction and on-line fluorescent detection of the counterion with applications
24. Pharmacokinetics of trichloroethanol and metabolites and interconversions among variously referenced pharmacokinetic parameters
25. Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N'-N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites
26. Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite
27. Protein binding and erythrocyte partitioning of the antirheumatic proquazone
28. Comparison of the erythrocyte partitioning method with two classical methods for estimating free drug fraction in plasma
29. 9-tetrahydrocannabinol
30. Binding of indapamide to serum proteins and erythrocytes
31. Multiple binding of bepridil in human blood
32. Binding of retelliptine, a new antitumoral agent, to serum proteins and erythrocytes
33. Assessment of cyclosporine A interactions with human plasma lipoproteins in vitro and in vivo in the rat
34. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique
35. Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes
36. The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum
37. Pharmacokinetics of morphine and its surrogates VI: Bioanalysis, solvolysis kinetics, solubility, pK'(a) values, and protein binding of buprenorphine
38. Cerivastatin, a new inhibitor of HMG-CoA reductase
39. BAY x 1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics
40. BAY x 3702 (-)-(R)-2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl) methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide monohydrochloride
41. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms
42. Plasmolysis, red blood cell partitioning, and plasma protein binding of etofibrate, clofibrate, and their degradation products